FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients ...Middle East

Osemitamab (TST001) on Track to Become a Global Therapy that Elevates the Current Standard of Care for HER2-Negative G/GEJ Adenocarcinoma PRINCETON, N.J. and SUZHOU, China, Oct. 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage...

Hence then, the article about fda grants transcenta clearance to proceed with global phase iii trial of osemitamab tst001 as first line treatment for gastric gastroesophageal cancer patients was published today ( Wednesday 04/10/2023 - 03:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients )

Also on site :

• ‘Fire Country’ Announces Major Change After Season 4 Cast Shake-Up
• Nearly 14,000 Pounds of Grilled Chicken Products Recalled for a Potentially Life-Threatening Reason—What to Know
• ‘Beloved’ Woodford Reserve Bourbon Is Back Nationwide